Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2017

Anelli V, Villefranc JA, Chhangawala S, Martinez-McFaline R, Riva E, Nguyen A, et al. Oncogenic BRAF disrupts thyroid morphogenesis and function via twist expression. Elife. 2017;6.

Cheng E, Ko D, Nguyen M, Moo T-, Andreopoulou E, Hoda SA, et al. Residual Pure Intralymphatic Breast Carcinoma Following Neoadjuvant Chemotherapy Is Indicative of Poor Clinical Outcome, Even in Node-Negative Patients. Am J Surg Pathol. 2017;41(9):1275-1282.

Sederdahl BK, Yi J, Jerris R, Gillespie SE, Westblade L, Kraft CS, et al. The Residual Vaccine-preventable Burden of Rotavirus Disease. Pediatr Infect Dis J. 2017;36(8):780-781.

Shukla S, Cyrta J, Murphy DA, Walczak EG, Ran L, Agrawal P, et al. Aberrant Activation of a Gastrointestinal Transcriptional Circuit in Prostate Cancer Mediates Castration Resistance. Cancer Cell. 2017;32(6):792-806.e7.

DeSimone RA, Wontakal SN, Lyashchenko AK, Schwartz J. Acute mechanical hemolysis as a complication of extracorporeal photopheresis in a low-weight child. J Clin Apher. 2017;32(6):571-573.

J Mulvey J, Matnani R, Cushing MM. Historical ABO blood group discrepancy: a blessing in disguise to unravel a medical identity theft. Transfusion. 2017;57(4):1096-1097.

Khani F, Epstein JI. In response to 'a plea for greater standardization' in intraductal carcinoma of the prostate: greater standardization requires greater evidence. Histopathology. 2017;70(6):1011-1013.

Magro CM, Olson LC, Fulmer CG. CD30+ T cell enriched primary cutaneous CD4+ small/medium sized pleomorphic T cell lymphoma: A distinct variant of indolent CD4+ T cell lymphoproliferative disease. Ann Diagn Pathol. 2017;30:52-58.

Fan J, Zhang H, Nguyen DT, Lyon CJ, Mitchell CD, Zhao Z, et al. Rapid diagnosis of new and relapse tuberculosis by quantification of a circulating antigen in HIV-infected adults in the Greater Houston metropolitan area. BMC Med. 2017;15(1):188.

Cayrol F, Praditsuktavorn P, Fernando TM, Kwiatkowski N, Marullo R, M Calvo-Vidal N, et al. THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors. Nat Commun. 2017;8:14290.